Article Text

Download PDFPDF
Commentary
Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study—determination of immunogenicity

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • ML and EB contributed equally.

  • Contributors Both authors contributed equally.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests ML received speaker honoraria, travel funding and research grants from Amicus Therapeutics, Chiesi, Sanofi Genzyme and Takeda. EB received research grants and speaker honoraria from Amicus Therapeutics, Chiesi, Eleva, Sanofi Genzyme and Takeda.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles